Lineage Cell Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LCTX research report →
Price Chart
About the company
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
- CEO
- Brian Culley
- IPO
- 1992
- Employees
- 75
- HQ
- Carlsbad, CA, US
Get TickerSpark's AI analysis on LCTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $195.26M
- P/E
- -27.15
- Fwd P/E
- 13.42
- PEG
- -0.15
- P/S
- 19.14
- P/B
- 3.09
- EV/EBITDA
- -84.86
- Div Yield
- 0.00%
- Gross Margin
- 95.88%
- Op Margin
- -280.34%
- Net Margin
- 16.18%
- ROE
- 3.10%
- ROIC
- 20.99%
Latest fiscal year · YoY change
- Revenue
- $14.56M+53.2%
- Gross Profit
- $13.71M+49.6%
- Op Income
- $-21,779,000
- Net Income
- $-63,533,000-241.4%
- EPS
- $-0.28-201.1%
- OCF Growth
- +18.1%
- FCF Growth
- +17.8%
- 52W High
- $1.99
- 52W Low
- $0.77
- 50D MA
- $0.98
- 200D MA
- $1.28
- Beta
- 1.69
- RSI (14)
- 37
- Avg Volume
- 1.62M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lineage announced a transformational acquisition of NeuroAirmid/HUNT1 while reporting a quarter with lower revenue, higher operating costs, and a cash runway extended into Q2 2028.· November 12, 2026
- Acquired NeuroAirmid and its HUNT1 Huntington’s disease cell therapy, adding a third clinical-stage asset alongside OpRegen and OPC1.
- Management said HUNT1 is already in Phase Ib/IIa, with 6 patients dosed and no serious adverse events reported to date.
- The company highlighted new platform progress, including a patent for AlloSCOPE 5D and first demonstration of islet cell precursor differentiation in a 5D system.
- Q3 revenue declined year over year, while operating expenses rose; the quarter also included large noncash warrant-related income that swung results to net income.
- Cash and securities of $45.2 million are expected to fund operations into Q2 2028, with additional potential capital from warrants and Roche/Genentech milestones.
Total revenue for the third quarter was approximately $1.5 million, down from $3.7 million in the same period of 2025, a decrease of $2.2 million. Operating expenses were approximately $8.8 million versus $7.5 million a year ago, including R&D of $3.8 million and G&A of $4.9 million. Loss from operations was $7.3 million compared with $3.8 million in the prior-year quarter. Other income was $12 million versus other expenses of $26 million last year, driven primarily by the fair value remeasurement of the warrant liability. Net income was $4.2 million, or $0.02 per share basic and $0.03 loss per share diluted, versus a net loss of $28 million, or $0.13 per share basic and diluted, in Q3 2025. As of September 30, 2026, the company had $45.2 million in cash, cash equivalents and marketable securities, which it expects will fund planned operations into the second quarter of 2028. On the HUNT1 transaction, Lineage said it paid $2.4 million in cash to NAM shareholders, issued approximately 2.2 million common shares worth $2.1 million, and made $1.9 million of third-party cash payments, for about $4.3 million in external cash outlays on day 1. Jill Howe said the company updated its run-rate guidance into Q2 2028, one quarter earlier than prior guidance. The company expects a final upfront installment on the first anniversary of closing of up to approximately $2.6 million cash, $2.4 million worth of common shares, and a $356,000 cash payment to CIRM. Remaining payments are contingent on clinical progress. Management said the REGEN4HD trial is funded by a $12 million CIRM grant, and Lineage expects its clinical costs for the program to be less than $2 million per year, including its obligation to co-fund up to $3.1 million. The company also said it remains eligible for approximately $32 million from warrant exercises and up to $615 million in development and commercial milestone payments under the Roche and Genentech collaboration.
Brian Culley framed the quarter as a strategic step-change, saying the acquisition of NeuroAirmid and HUNT1 completes what he called Lineage 3.0 and broadens the company’s neurology pipeline. He emphasized that Lineage already had rights to the underlying cell line, has manufacturing experience that can industrialize the program, and believes the deal fits the company’s capital-efficient approach. His tone was highly confident and expansive, with repeated emphasis on differentiation, platform leverage, and long-term value creation.
Jill Howe focused on the transaction economics and runway. She said Lineage paid $2.4 million in cash to NAM shareholders, issued about 2.2 million shares worth $2.1 million, and paid $1.9 million to third parties, for about $4.3 million of day-one external cash outlays. She noted the company had $45.2 million in cash, cash equivalents and marketable securities at September 30, 2026, expected to fund operations into Q2 2028, and reiterated potential additional capital from roughly $32 million of warrant proceeds and up to $615 million in Roche/Genentech milestones. On the existing business, she said the new HUNT1 program should cost less than $2 million per year for Lineage, including co-funding obligations, and fit within the company’s historic roughly $30 million annual budget run rate.
Analysts focused mainly on HUNT1’s early data, immunosuppression, manufacturing scale-up, and what would count as success versus stabilization or improvement. Management said the study remains primarily a safety study, but they are watching early functional and biomarker signals such as UHDRS-derived measures, TFC, SDMT, MRI, FDG-PET, and fluid biomarkers like NfL and proenkephalin. On manufacturing, Brian Culley said Lineage has started work on a GMP master cell bank and already has material to support all 21 patients in the current study, while future industrialized manufacturing will require bridging/comparability work. Management also said it has more insight into the ongoing study than in some partnered programs because it sits on the strategic planning committee, but it still does not control the academic sponsor’s disclosure timing.
The bullish case from this call is that Lineage added a clinical-stage Huntington’s asset with what management sees as a differentiated cell-replacement mechanism, backed by early safety data and external grant funding. The company also showed continued progress across its platform, including new patent protection, scale-up of 5D manufacturing, and early preclinical advancement in multiple internally developed programs.
The main risks are that HUNT1 is still very early, with only 6 patients dosed and efficacy still unproven, while any future industrial manufacturing will need bridging/comparability work. Revenue fell year over year, operating expenses increased, and the company remains reliant on partnered programs, grants, and future milestones for meaningful value realization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.9%
- Shares Outstanding
- 252.95M
- Float Shares
- 240.00M
of shares held by institutions
136 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for LCTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Anna Paulina LunaHouse · FL13 | Sell | Jan 2, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Broadwood Capital Inc | 49.56M | 0 |
| Blackrock, Inc. | 13.87M | ▲ 683.98K |
| Vanguard Group Inc | 9.64M | ▲ 637.35K |
| Vanguard Capital Management LLC | 8.78M | ▼ 279.25K |
| Defender Capital, LLC. | 6.65M | ▲ 50.00K |
| Geode Capital Management, LLC | 5.34M | ▲ 39.90K |
| Raffles Associates LP | 5.20M | ▼ 165.00K |
| Fifth Third Bancorp | 4.90M | ▲ 300.00K |
| Comerica Bank | 4.60M | 0 |
| Millennium Management LLC | 3.02M | ▼ 2.54M |
| State Street Corp | 2.93M | ▲ 611.55K |
| Vanguard Fiduciary Trust Co | 1.72M | ▲ 46.50K |
Held by 88 ETFs
Biggest fund positions in LCTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | BROADWOOD PARTNERS, L.P. | buy | 1,000,000 |
| Nov 17, 26 | BROADWOOD PARTNERS, L.P. | buy | 0 |
| Nov 17, 26 | Mulroy Michael H. | buy | 30,000 |
| Nov 16, 26 | ANDREWS DEBORAH J | buy | 25,000 |
| Nov 16, 26 | Culley Brian M | buy | 40,500 |
| Nov 16, 26 | Howe Jill Ann | buy | 20,000 |
| Jul 1, 26 | Bradsher Neal C | other | 125,000 |
| Jul 1, 26 | Jayasuriya Anula | other | 125,000 |
| Jul 1, 26 | Mulroy Michael H. | other | 125,000 |
| Jul 1, 26 | ANDREWS DEBORAH J | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LCTX coverage
Recent articles, reports, and earnings notes.
No research on LCTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LCTX report →What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 13
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 12
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
businesswire.com · Nov 12
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington's Disease
businesswire.com · Nov 12
Lineage Provides Update on ReSonance® Program for Hearing Loss
businesswire.com · Oct 29
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Climb 8.7% – Here’s What Happened
defenseworld.net · Sep 27
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
businesswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.